Psoriatic Arthritis 
The MD Magazine Psoriatic Arthritis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

Is Psoriatic Arthritis a Risk Factor for Vascular Disease?
New research comparing patients and controls suggests that the body’s inflammatory response to psoriatic arthritis can lead to atherosclerosis and then to cardiovascular disease.
The gut microbiome has previously been considered a therapeutic target for the immune system, and new research suggests the microbiome’s composition can hold the key to managing psoriasis.
Philip J. Mease, MD, and John D. Reveille, MD, discuss the safety and efficacy of considering a new treatment for spondyloarthritis, specifically the use of IL-17 inhibition and methotrexate.
The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).
John D. Reveille, MD, and Philip J. Mease, MD, highlight the newer mechanisms of action in ankylosing spondylitis and psoriatic arthritis.
John D. Reveille, MD, and Philip J. Mease, MD, outline the inflammatory pathways in ankylosing spondylitis and psoriatic arthritis, as well as mention the newer mechanism of action.
Most psoriatic arthritis patients can maintain low disease activity on reduced doses of tumor necrosis factor inhibitors — but patients who experience flares after switching to the lower dose can struggle to regain control over their disease.
A new study found that female psoriasis patients have a fourfold increased risk of developing Crohn’s disease (CD).
Type X collagen, which is expressed by hypertrophic chondrocytes, is suppressed by tumor necrosis factor alpha inhibitors (TNFi) treatments, arthritis researchers report.The finding could lead to a molecular marker for early diagnosis of psoriatic arthritis and axial spondyloarthritis.

Most Popular


$vacMongoViewPlus$ $vAR$